Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome
- 14 January 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 115 (2) , 388-395
Abstract
In Budd-Chiari syndrome (BCS), thrombosis develops in the hepatic veins or inferior vena cava. To study the relationship between hypofibrinolysis and BCS, we measured plasma levels of fibrinolysis proteins in 101 BCS patients and 101 healthy controls and performed a plasma-based clot lysis assay. In BCS patients, plasminogen activator inhibitor 1 (PAI-1) levels were significantly higher than in controls (median, 6.3 vs 1.4 IU/mL, P < .001). Thrombin-activatable fibrinolysis inhibitor and plasmin inhibitor levels were lower than in controls (13.8 vs 16.9 μg/mL and 0.91 vs 1.02 U/L, both P < .001). Median plasma clot lysis time (CLT) was 73.9 minutes in cases and 73.0 minutes in controls (P = .329). A subgroup of cases displayed clearly elevated CLTs. A CLT above the 90th or 95th percentile of controls was associated with an increased risk of BCS, with odds ratios of 2.4 (95% confidence interval, 1.1-5.5) and 3.4 (95% confidence interval, 1.2-9.7), respectively. In controls, only PAI-1 activity was significantly associated with CLT. Analysis of single nucleotide polymorphisms of fibrinolysis proteins revealed no significant differences between cases and controls. This case-control study provides the first evidence that an impaired fibrinolytic potential, at least partially caused by elevated PAI-1 levels, is related to the presence of BCS.Keywords
This publication has 51 references indexed in Scilit:
- Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous ThrombosisPLOS Medicine, 2008
- Hemostatic Alterations in Liver Disease: A Review on Pathophysiology, Clinical Consequences, and TreatmentDigestive Surgery, 2007
- Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosisThrombosis and Haemostasis, 2007
- Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC‐Norfolk prospective population studyJournal of Thrombosis and Haemostasis, 2006
- Reduced plasma fibrinolytic potential is a risk factor for venous thrombosisBlood, 2005
- Budd–Chiari syndrome: a review by an expert panelJournal of Hepatology, 2003
- Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factorsHepatology, 2000
- FACTOR XIII DEFICIENCYBritish Journal of Haematology, 1999
- Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Status in Budd-Chiari SyndromePathophysiology of Haemostasis and Thrombosis, 1996
- Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders.The Tohoku Journal of Experimental Medicine, 1982